Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Sanofi Pasteur MSD
Femme Max 99 ans
Sanofi Pasteur MSD S.N.C
MAJ Il y a 4 ans
A clinical trial to study the antibody response and tolerability of GARDASIL®9 in women aged 27 to 45 years old compared to women aged 16 to 26 years old
To demonstrate that the administration of GARDASIL®9 in 27- to 45 year old women induces non inferior geometric mean titres (GMTs) for serum anti-HPV 16, 18, 31, 33, 45, 52, and 58 compared with 16- t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur MSD S.N.C
MAJ Il y a 4 ans
study of the immunogenicity and safety of a decoy dose of HBVAXPRO®, in healthy children vaccinated 10 years ago with 3 doses of HEXAVAC® or INFANRIX®-HEXA. studio sull'immunogenicità e sulla sicurezza della dose di richiamo con HBVAXPRO®, in bambini sani vaccinati 10 prima con 3 dosi di HEXAVAC® o INFANRIX®-HEXA
*To describe, in subjects vaccinated with 3 doses of HEXAVAC® as infants, the percentage of subjects with an anti-HBs concentration ≥10 mIU/mL one month after a challenge dose of HBVAXPRO® given at le...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur MSD
MAJ Il y a 4 ans
Comparison of the immunogenicity and safety of a combined adsorbed low dose diphtheria, tetanus and inactivated poliomyelitis vaccine (REVAXIS®) with a combined diphtheria, tetanus and inactivated poliomyelitis vaccine (DT Polio®) when given as a booster dose at 6 years of age
To demonstrate that the Diphtheria seroprotection response (defined as anti-diphtheria antibody titre (SN) ≥ 0.1 IU/mL), the Tetanus seroprotection response (defined as an anti-tetanus antibody titre ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur MSD S.N.C
MAJ Il y a 4 ans
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of the concomitant use of a live pentavalent rotavirus vaccine (RotaTeq®) and a meningococcal group C conjugate (MCC) vaccine in healthy infants
To demonstrate that RotaTeq® can be administered concomitantly with MCC vaccine to healthy infants without impairing the antibody seroprotection rate to meningococcal Group C serotype as measured by s...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur MSD S.N.C
MAJ Il y a 4 ans
A new vaccine for babies which adds protection against hepatitis B
To evaluate the concomitant administration of PR5I with two types of MCC vaccines (MCC-TT and MCC-CRM) to healthy infants at 3 and 4 months of age in term of antibody seroprotection rate (SPR) to MCC.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur MSD S.N.C
MAJ Il y a 4 ans
A Study to Estimate the Immune Response Following a Challenge Dose in Adults (≥ 50 years old) Vaccinated With a Primary Series of an Hepatitis B Vaccine
To describe the Seroprotection rate (SPR) at least 2 years following completion of a primary series of modified process RECOMBIVAX HB™ ( HBVaxPRO) and 1 month following a challenge dose of modified pr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur MSD
MAJ Il y a 4 ans
A phase 3 open-label study to evaluate the immune response and the safety of a primary series schedule that includes V419 (PR5I: hexavalent vaccine) at 2 and 6 months of age and Pediacel® (pentavalent vaccine) at 4 months of age Estudio abierto fase III para evaluar la respuesta inmune y la seguridad de un esquema de primovacunación que incluye V419 (PR5I: vacuna hexavalente) a los 2 y 6 meses de edad y Pediacel® (vacuna pentavalente) a los 4 meses de edad
The two co-primary objectives for the study are: -To demonstrate that the mixed schedule induces acceptable responses for Hepatitis B (% of subjects with an anti-HBs titre ≥10 mIU/mL ) one month after...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur MSD SNC
MAJ Il y a 4 ans
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 2-dose regimen of ProQuad® manufactured with rHA administered to healthy children from 9 months of age
The first primary objective is to demonstrate that a 2-dose regimen of ProQuad® rHA administered at a 3-month interval to healthy childrenof 11 months of age at the time of Dose 1 is as immunogenic ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur MSD S.N.C
MAJ Il y a 4 ans
A controlled, double-blind and randomized study, to compare the immunogenicity and safety of HEXAVAC manufactured by an upgraded process to HEXAVAC manufactured by the current process when given to healthy infants at 2, 4 & 6 months of age followed by a booster dose at 12 months of age
1. To show, that when HEXAVAC® upgraded process is given in a 3-dose primary series at 2, 4 and 6 months of age, followed by a booster dose at 12 months the anti-HBs seroprotection rate one month post...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur MSD S.N.C
MAJ Il y a 4 ans
An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured with Recombinant Human Albumin (rHA) when administered to Children in their Second Year of Life
To describe the safety profile of a second dose of ProQuad® manufactured with rHA when administered to children in their second year of life
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
Suivant